Last Update 20 Feb 26

Fair value Decreased 23%

AMWL: Cost Discipline And Extended Elevance Agreement Will Shape Balanced 2026 Outlook

The analyst price target for American Well has been reduced by $1.88, from $8.13 to $6.25. Analysts cite softer revenue growth assumptions, slightly lower profit margin expectations, and a modestly lower future P/E multiple, as reflected in recent target cuts at firms including TD Cowen and Stifel.

Analyst Commentary

Analysts are adjusting their models for American Well in light of revised growth and profitability expectations, which is feeding directly into the lower price targets you are seeing. Here is how the debate is shaping up on both the upside and the risk side.

Bullish Takeaways

Bullish analysts see the new US$6.25 target as still allowing for upside if the company can deliver on revenue execution after the recent reset in growth assumptions.
They view the trimmed profit margin expectations as giving management a bit more room to invest in operations without being judged against overly tight near term profitability hurdles.
The slightly lower future P/E multiple embedded in targets is seen as leaving less room for further valuation compression if business performance stays broadly in line with current assumptions.
Bullish analysts tend to frame the target cut as a calibration of inputs, not a fundamental shift in their long term view of the company’s role in telehealth services.

Bearish Takeaways

Bearish analysts focus on the softer revenue growth assumptions as a sign that it may take longer for American Well to scale into its addressable market, which can cap share price upside.
They see the lower profit margin expectations as a potential signal that operating leverage could be slower to materialize, putting more pressure on management to control costs.
The modestly lower future P/E multiple in models suggests to them that investors may be less willing to pay up for the stock without clearer evidence of consistent execution.
Some bearish analysts treat the cluster of target cuts as a caution flag that expectations around growth and margins had been set too high, which can keep sentiment more subdued for a period.

What’s in the News

American Well extended its Master Services Agreement with Elevance Health, originally dated January 1, 2023, with a new term starting January 1, 2026 and running through January 1, 2029. The agreement will then renew automatically for successive one year periods unless either party ends the deal. (Key Developments)
The company will continue to operate a white labelled digital care delivery platform for Elevance Health under the LiveHealth Online brand. Elevance Health is obligated to pay annual subscription fees and may engage American Well for additional professional, development, innovation and engagement marketing services. (Key Developments)
A new Healthy Impact Statement of Work, entered into on December 25, 2025 and effective January 1, 2026, updates American Well’s Healthy Impact service offerings for Elevance Health and aligns these services with the extended MSA term. (Key Developments)
Online Care Group, PC, American Well’s clinical partner, amended two provider agreements with Elevance Health related entities so a 50 state clinician network will continue to deliver digital care consultations via LiveHealth Online through January 1, 2029. These agreements will automatically renew for successive one year periods thereafter. (Key Developments)
The extended commercial agreements and the provider agreements allow termination for material breach, bankruptcy or other specified events. Elevance Health also retains the ability to terminate certain agreements for convenience with 365 days’ written notice. (Key Developments)

Valuation Changes

Fair Value: target reduced from $8.13 to $6.25, a cut of about 23% that aligns with the updated analyst price target mentioned earlier.
Discount Rate: moved slightly lower from 8.42% to 8.28%, implying a modest adjustment to the risk or required return assumption used in the model.
Revenue Growth: long term revenue growth assumption shifted from about a 2.07% decline to a 4.44% decline, indicating a more conservative view on top line trends.
Net Profit Margin: margin input is slightly lower, from 7.11% to 6.93%, reflecting a small reduction in expected profitability over time.
Future P/E: terminal P/E assumption reduced from 10.54x to 9.47x, suggesting a lower valuation multiple applied to future earnings in the updated model.

3 views

Key Takeaways

Integrated AI, expanded service offerings, and deepening relationships with major clients are driving strong recurring revenue growth and positioning for future upselling.
Ongoing cost reductions and a shift to higher-margin software are improving profitability, supporting a credible path toward sustained positive cash flow.
Revenue predictability is challenged by declining visit volumes, volatile contract renewals, reliance on non-recurring revenue, ongoing losses, and heightened competitive and macro risks.

Catalysts

About American Well

An enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally.What are the underlying business or industry changes driving this perspective?

The ongoing transition of healthcare systems toward more accessible, technology-enabled care is driving increased adoption of digital platforms; management cited expanding deployments (e.g., Military Health System, Florida Blue), underlining a robust pipeline and positioning Amwell for sustained revenue growth as virtual care becomes mainstream.
The significant integration of AI capabilities across Amwell's platform-including automation, clinical decision support, and data analytics-aligns with rising demand for more efficient, data-driven value-based care, supporting improved gross margins and accelerating the path to profitability.
Deepening relationships and contract extensions with large, long-term clients like the Department of Defense (Military Health System) and Florida Blue not only support predictable recurring revenues but also create a foundation for future expansion and upselling of higher-margin services, boosting both revenue and net margins.
Amwell's focus on expanding its digital health service offerings, along with the platform's capability for rapid deployment of additional programs (such as behavioral health and chronic disease management), increases the company's addressable market and provides upside for both revenue and earnings as clients normalize budgets and add new services.
A concerted effort to streamline operations, reduce operating costs, and shift revenue mix toward higher-margin subscription software is resulting in improved adjusted EBITDA and a credible path to positive operating cash flow by 2026, pointing to long-term net margin and earnings potential.

American Well Earnings and Revenue Growth

American Well Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming American Well's revenue will neither grow nor shrink over the next 3 years.
Analysts are not forecasting that American Well will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate American Well's profit margin will increase from -46.2% to the average US Healthcare Services industry of 8.8% in 3 years.
If American Well's profit margin were to converge on the industry average, you could expect earnings to reach $23.6 million (and earnings per share of $1.31) by about September 2028, up from $-124.5 million today.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 9.1x on those 2028 earnings, up from -0.9x today. This future PE is lower than the current PE for the US Healthcare Services industry at 54.8x.
Analysts expect the number of shares outstanding to grow by 5.43% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.95%, as per the Simply Wall St company report.

American Well Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

The one-year renewal of the Military Health System (DHA) contract (rather than a multi-year agreement) and the exclusion of behavioral health and automated care programs due to Department of Defense budget cuts introduce heightened revenue concentration risk and create uncertainty about the stability and duration of high-margin government contract revenues, which can affect revenue predictability and overall top-line growth.
Sustained decline in total visit volumes (down 22.3% year-over-year for Q2) and significant declines in Amwell Medical Group (AMG) visit revenue (down 20.8% year-over-year), when combined with a flattish outlook post-normalization, suggest longer-term challenges in maintaining user engagement and utilization rates, potentially suppressing revenue per visit and limiting EPS growth.
Heavy reliance on non-recurring subscription software revenue (due to the timing of customer go-lives and initial deployments, especially with the Military Health System) results in top-line volatility and questions around the sustainability and scalability of recurring, high-margin revenue-directly impacting future revenue growth and net margins.
While cost reductions in R&D, sales and marketing, and G&A have favorably improved adjusted EBITDA and delayed cash burn, the business is still operating at a loss and is targeting breakeven only by 2026; continued net losses and negative operating cash flow may necessitate further capital raises, leading to dilution risk for shareholders and ongoing pressure on net income.
Macro uncertainty (regulatory changes, provider and payer budget constraints), increased competitive pressure from both large incumbents and new digital health entrants, and possible pricing pressure from growing market consolidation all threaten Amwell's ability to win, renew, or expand major contracts, which could compress margins and lower EBITDA in the long term.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $9.5 for American Well based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $12.0, and the most bearish reporting a price target of just $7.5.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $269.8 million, earnings will come to $23.6 million, and it would be trading on a PE ratio of 9.1x, assuming you use a discount rate of 8.0%.
Given the current share price of $6.96, the analyst price target of $9.5 is 26.7% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on American Well?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Digital Platforms And AI Will Reshape Future Healthcare